The underlying principle of cytokine mediated gene therapy involves tumor-selective gene transfer and in situ expression of various cytokine genes such as IL-2, −4, −12, and interferon (IFN)-β, −γ which can induce robust immune responses restricted to antigens specific to glioma cells [17, 37, 77, 154]. This evidence concerns the gene IL2 and glioma.